Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
| Market Capitalization | $309.3978 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | 0 |
| Book Value | 0.617 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.17 |
| EBITDA | -66,843 |
| Profit Margin | 0 |
| Operating Margin TTM | -9.2373 |
| Return on Assets TTM | -0.0651 |
| Return on Equity TTM | -0.164 |
| Revenue TTM | 7,501 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2005-06-30 | 502.885 | 1,489.428 | ||
| 2006-06-30 | 2,821.758 | 9,105.844 | ||
| 2007-06-30 | 1,679.317 | 8,692.78 | ||
| 2008-06-30 | 909.807 | 8,849.388 | ||
| 2009-06-30 | 890.708 | 10,319.702 | ||
| 2010-06-30 | 5.5 | 11,132.134 | ||
| 2011-06-30 | 120,921.285 | 27,159.524 | ||
| 2012-06-30 | 38,279.902 | 21,637 | 64,987.39 | |
| 2013-06-30 | 28,786 | 20,174 | 88,864 | |
| 2014-06-30 | 25,980 | 26,488 | -2,044 | 98,356 |
| 2015-06-30 | 23,748 | 23,783 | -4,022 | 137,139 |
| 2016-06-30 | 42,548 | 29,763 | 12,785 | 98,436 |
| 2017-06-30 | 2,412 | 12,065 | -9,653 | 92,454 |
| 2018-06-30 | 17,341 | 5,508 | 11,833 | 92,191 |
| 2019-06-30 | 16,722 | 15,358 | 16,722 | 97,884 |
| 2020-06-30 | 32,156 | 25,309 | 32,156 | 107,561 |
| 2021-06-30 | 7,456 | 32,719 | 7,456 | 115,059 |
| 2022-06-30 | 10,211 | 30,757 | 10,211 | 90,785 |
| 2023-06-30 | 7,501 | 27,733 | 7,501 | 76,790 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2005-06-30 | 15,093.834 | 21,465.824 | 2,203.068 | 20,668 | ||
| 2006-06-30 | 7,854.843 | 16,384.515 | 4,419.47 | 20,668 | ||
| 2007-06-30 | 12,055.04 | 21,238.238 | 698.899 | 37,422 | ||
| 2008-06-30 | 14,094.219 | 27,788.902 | 1,572.77 | 51,019 | ||
| 2009-06-30 | 16,526.278 | 26,975.012 | 1,185.05 | 62,460 | ||
| 2010-06-30 | 32,049.327 | 39,514.77 | 1,595.51 | 87,949 | ||
| 2011-06-30 | 263,227.585 | 763,250.507 | 247,406.334 | 477,115 | ||
| 2012-06-30 | 206,748.798 | 720,455.55 | 241,607.767 | 485,004 | ||
| 2013-06-30 | 315,309 | 883,712 | 253,446 | 654,458 | ||
| 2014-06-30 | 196,394 | 899,314 | 327,596 | 677,087 | ||
| 2015-06-30 | 144,142 | 1,017,925 | 408,566 | 737,260 | ||
| 2016-06-30 | 80,937 | 684,018 | 155,857 | 770,272 | ||
| 2017-06-30 | 45,761 | 655,686 | 138,920 | 0 | 830,425 | |
| 2018-06-30 | 37,763 | 692,443 | 146,435 | 59,397 | 59,397 | 889,481 |
| 2019-06-30 | 50,426 | 652,115 | 171,063 | 14,007 | 67,279 | 910,405 |
| 2020-06-30 | 129,328 | 733,602 | 184,276 | 35,974 | 57,023 | 1,051,450 |
| 2021-06-30 | 136,881 | 744,717 | 163,320 | 55,965 | 41,045 | 1,163,153 |
| 2022-06-30 | 60,034 | 662,142 | 165,098 | 8,203 | 91,617 | 1,165,309 |
| 2023-06-30 | 70,920 | 669,415 | 167,577 | 10,012 | 102,811 | 1,249,123 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2005-06-30 | -1,470.369 | -604.812 | 15,093.834 | |||
| 2006-06-30 | -8,298.587 | -3,183.863 | -7,238.991 | 15,093.834 | 7,854.843 | |
| 2007-06-30 | -8,728.131 | -9,102.676 | 4,200.197 | 7,854.843 | 12,055.04 | |
| 2008-06-30 | -10,062.379 | -6,202.589 | 2,039.179 | 12,055.04 | 14,094.219 | |
| 2009-06-30 | -12,285.459 | -9,237.576 | 2,432.059 | 14,094.219 | 16,526.278 | |
| 2010-06-30 | -14,780.895 | -9,657.662 | 15,523.049 | 16,526.278 | 32,049.327 | |
| 2011-06-30 | 90,606.59 | 108,228.873 | 231,178.258 | 32,049.327 | 263,227.585 | |
| 2012-06-30 | -71,145.314 | -72,116.783 | -56,478.787 | 263,227.585 | 206,748.798 | |
| 2013-06-30 | -61,663 | -54,081 | 109,718 | 205,591 | 315,309 | |
| 2014-06-30 | -80,958 | -81,861 | -118,915 | 315,309 | 196,394 | |
| 2015-06-30 | -119,368 | -121,709 | -52,252 | 196,394 | 144,142 | |
| 2016-06-30 | -4,127 | -87,996 | -29,764 | 110,701 | 80,937 | |
| 2017-06-30 | -76,815 | -95,471 | -35,176 | 80,937 | 45,761 | |
| 2018-06-30 | -35,290 | -75,012 | -7,998 | 45,761 | 37,763 | |
| 2019-06-30 | -89,799 | -57,790 | 12,663 | 37,763 | 50,426 | |
| 2020-06-30 | -77,940 | -56,365 | 78,902 | 50,426 | 129,328 | 0 |
| 2021-06-30 | -98,811 | -106,681 | 7,553 | 129,328 | 136,881 | |
| 2022-06-30 | -91,347 | -65,782 | -76,434 | 136,881 | 60,447 | 0 |
| 2023-06-30 | -81,889 | -63,269 | 10,871 | 60,447 | 71,318 | 0 |